

# UC Riverside

## UC Riverside Previously Published Works

### Title

Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinsons Disease.

### Permalink

<https://escholarship.org/uc/item/9q8019sb>

### Journal

CNS Drugs, 32(4)

### Authors

Elmer, Lawrence

Juncos, Jorge

Singer, Carlos

et al.

### Publication Date

2018-04-01

### DOI

10.1007/s40263-018-0510-z

Peer reviewed

## Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease

Lawrence W. Elmer<sup>1</sup> · Jorge L. Juncos<sup>2</sup> · Carlos Singer<sup>3</sup> · Daniel D. Truong<sup>4</sup> · Susan R. Criswell<sup>5</sup> · Sotirios Parashos<sup>6</sup> · Larissa Felt<sup>7</sup> · Reed Johnson<sup>7</sup> · Rajiv Patni<sup>7</sup>

Published online: 10 April 2018  
© Springer International Publishing AG, part of Springer Nature 2018

**Author Correction to: CNS Drugs**  
<https://doi.org/10.1007/s40263-018-0498-4>

An Online First version of this article was made available online at <http://link.springer.com/journal/40263/onlineFirst/page/1> on 12 March 2018. An error was subsequently identified in the article, and the following correction should be noted:

Table 2, Primary efficacy results for the phase III studies and pooled populations at week 12: in the 'Pooled' section of the table, the 'Placebo' and 'ADS-5102' column headings are transposed. The corrected table is shown in the following page.

The original article has been corrected.

---

The original article can be found online at <https://doi.org/10.1007/s40263-018-0498-4>.

---

✉ Lawrence W. Elmer  
Lawrence.Elmer@utoledo.edu

- <sup>1</sup> Department of Neurology, University of Toledo College of Medicine, 3120 Glendale Avenue, Toledo, OH 43614, USA
- <sup>2</sup> Department of Neurology and Movement Disorders, Emory University School of Medicine, Atlanta, GA, USA
- <sup>3</sup> Department of Neurology, University of Miami, Miami, FL, USA
- <sup>4</sup> The Parkinson's and Movement Disorder Institute, Fountain Valley, CA, USA
- <sup>5</sup> Department of Neurology, Washington University, St. Louis, MO, USA
- <sup>6</sup> Struthers Parkinson's Center, Golden Valley, MN, USA
- <sup>7</sup> Adamas Pharmaceuticals, Inc., Emeryville, CA, USA

**Table 2** Primary efficacy results for the phase III studies and pooled populations at week 12

Parameter	EASE LID				EASE LID 3				Pooled			
	LS mean change from baseline (SE)				LS mean change from baseline (SE)				LS mean change from baseline (SE)			
	ADS-5102 [n = 63]	Placebo [n = 58]	Treatment difference <sup>a</sup> [95% CI]	p value <sup>b</sup>	ADS-5102 [n = 37]	Placebo [n = 38]	Treatment difference <sup>a</sup> [95% CI]	p value <sup>b</sup>	ADS-5102 [n = 100]	Placebo [n = 96]	Treatment difference <sup>a</sup> [95% CI]	p value <sup>b</sup>
UDysRS total score, absolute	-15.9 (1.6)	-8.0 (1.6)	-7.9 (-12.5, -3.3)	0.0009	-20.7 (2.2)	-6.3 (2.1)	-14.4 (-20.4, -8.3)	<0.0001	-17.7 (1.3)	-7.6 (1.3)	-10.1 (-13.8, -6.5)	<0.0001
UDysRS total score, relative, %	-37.0 (5.8)	-11.6 (5.9)	-25.4 (-41.7, -9.0)	0.0027	-45.8 (5.2)	-16.3 (4.9)	-29.6 (-43.9, -15.3)	<0.0001	-41.1 (4.2)	-13.9 (4.1)	-27.3 (-38.7, -15.8)	<0.0001
UDysRS historical score (Parts I and II)	-9.9 (1.0)	-5.4 (1.0)	-4.5 (-7.4, -1.6)	0.0027	-12.1 (1.5)	-4.0 (1.4)	-8.1 (-12.1, -4.1)	0.0001	-10.7 (0.86)	-5.1 (0.84)	-5.6 (-8.0, -3.3)	<0.0001
UDysRS objective score (Parts III and IV)	-6.1 (0.9)	-2.7 (1.0)	-3.4 (-6.1, -0.8)	0.0120	-8.7 (1.3)	-2.2 (1.2)	-6.5 (-10.1, -3.0)	0.0004	-7.0 (0.76)	-2.5 (0.75)	-4.5 (-6.6, -2.4)	<0.0001

CI confidence interval, LS least squares, SE standard error, UDysRS Unified Dyskinesia Rating Scale

<sup>a</sup>ADS-5102–placebo

<sup>b</sup>p values are based on the comparison of ADS-5102 versus placebo from the mixed effect model repeat measurement model